IOL Chemicals & Pharmaceuticals Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/8uhawzgtvnit2mvbwokfyczg.pdf

Key Takeaways


The Ibuprofen Reset

Chaturvedi: "most certainly this is the lowest level of Ibuprofen crisis that we have seen in the last couple of years."

Chemical Business: A Margin Flip and a Promise

Chaturvedi: "I want to look at this as an average of what we do rather than a quarter-by-quarter. So, the message I want to leave you with... is the business is not under threat."

Diversification: The Build Phase

Non-Ibuprofen Pharma

Paracetamol

New Chemical Products

Chaturvedi: "There is a thumb rule to remember is if you want to have a significant growth in a business that business must grow by at least double digits, 10% to 20%. So, that is a kind of figure that we are targeting initially, and the idea is to add that kind of growth in a sustained way."

Margin Architecture and the Path Back

Chaturvedi: “I would much rather promise my investors 18, 20% EBITDA level, then show a yin-yang between 30, 35% back to 10% and then back to 30%, because that story is not sustainable.”

Portfolio Reshaping and Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Ibuprofen volume recoveryVolume uptick to beginFrom Q2 FY23 onwards
Ibuprofen pricing recoveryPrices to increase from current floor, driven by input cost pressureH2 FY23, once overstocking resolves
Chemical business EBITDAReturn to positive single digitsQ1 FY23
Chemical business EBITDAReturn to 6–8% rangeFY23 (full year)
Overall company EBITDA margin15% plusFY23
Overall company EBITDA margin18–20% average3–4 year journey
Non-Ibuprofen API EBITDA marginDouble digitsFY23
Non-Ibuprofen asset utilizationImprove to 75–80%Next 12–18 months
Paracetamol capacityDouble to 3,600 tons/yearEnd of CY22
New chemical products commercial activityRevenue contribution to beginFY24
Chemicals division growth rate10–20% sustained annual growthOngoing target
Ibuprofen share of pharmaLess than 50%Within 3 years
Backward integration in key non-IBU productsAchieved wherever possibleBy 2025
Export contributionIncrease to 35%No fixed date
Metformin regulated market approvalsEntry into regulated export marketsA few more quarters
FY23 CAPEX~₹250 croreFY23

Key Metrics

MetricQ4 FY22
Total revenue₹573 cr, up 3% QoQ from ₹555 cr in Q3 FY22
FY22 revenue growth11% YoY
EBITDA₹50 cr
FY22 EBITDA margin13%
FY22 profit after tax₹166 cr, down from ₹445 cr in FY21
Pharma segment EBIT margin37.27% (per an analyst's math)
Chemicals business EBITDA guidance6% to 8% annual average
Non-Ibuprofen pharma contribution to quarterly revenue20%
Non-Ibuprofen pharma contribution to pharma segment revenue35%
Ibuprofen asset utilization~70%
Ibuprofen volume decline FY22 vs FY21~1,000 tons
Ibuprofen FY22 volumes8,000–8,300 tons (per an analyst's math)
Ibuprofen FY22 average pricing$11 to $11.5 per kg
Ibuprofen installed capacity12,000 tonnes, vs world capacity of 35,000–36,000 tons
Paracetamol capacity1,800 tons per year, expanding to 3,600 tons by end of FY23
Exports contribution to revenue25–30%, with intent to reach 35%
FY23 planned CAPEX₹250 cr, up from historical average of ₹150 cr
FY23 EBITDA margin target15% plus, with 3–4 year target of 18–20%
USFDA DMFs filed in Q41
USFDA DMFs filed in FY224
CEP applications filed with EDQM in FY223
Patent applications filed in FY223